Fundraising Fox

Goldman Sachs2024 Investments

5 investments dated 2024 · listed companies and verified rows first · show all

Canoe Intelligencecanoeintelligence.cominJul 2024 · $36M

Canoe Intelligence provides document and data management software for institutional investors and wealth managers handling alternative investments, designed to automate workflows in private capital administration and reporting.

AI & Machine LearningEnterprise SoftwareFintechSaaS

Jason Eiswerth(CEO)Noel Calhoun(CTO)

Co-investorsF-Prime CapitalInner Loop Capital

Digitdigit.bioinMay 2024 · $141M

Digital Biology (Digit Bio) develops precision biologics and combination therapies for solid tumors, using its M×P (Molecules × Phenotypes) Platform that combines high-resolution imaging, next-generation sequencing, computation, and AI to map the spatial molecular organization of tumor tissues.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsFifty YearsA91 PartnersHSBCMorgan StanleySteadview Capital

Human Securityhumansecurity.comin𝕏Oct 2024 · $50M

HUMAN is a cybersecurity company focused on detecting and stopping automated bot attacks and digital fraud.

AdTechAI & Machine LearningCybersecurityEnterprise SoftwareSaaSBrooklyn, US

Tamer Hassan(Co-founder)Michael Tiffany(Co-founder)Dan Kaminsky(Co-founder)Ash Kalb(Co-founder)

Co-investorsCanaan PartnersDCVC (Data Collective)Evolution VC PartnersGrit Capital PartnersGula Tech AdventuresNightDragon+2 more

Simetriksimetrik.cominFeb 2024 · $55M

Simetrik provides AI-powered automation software for financial operations, specifically reconciliation and transaction matching across payment processors and platforms.

AI & Machine LearningEnterprise SoftwareFintechSaaSBogotá, CO

Alejandro Casas(Founder/CEO)inSantiago Gomez(Founder/CFO/COO)in

Co-investorsAmador HoldingsCapria VenturesClocktower VenturesFinTech CollectiveMONASHEESY Combinator+2 more

TORL BioTherapeuticsApr 2024

Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.

BiotechCulver City, US

Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)

Co-investorsOCV PartnersCowen Healthcare InvestmentsPerceptive Xontogeny VentureVertex Ventures HC

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.